Name: Name:(R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate
Brand: AABLOCKS
SKU: AA001ZR1
Rating: 90 (10 reviews)

Catalog No.: AA001ZR1

174649-09-3 | (R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate

Pack Size： 1g

Purity： 97%

in stock

$7.00 $5.00

Pack Size： 25g

Purity： 97%

in stock

$69.00 $48.00

Pack Size： 100g

Purity： 97%

in stock

$240.00 $168.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA001ZR1

Chemical Name: (R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate

CAS Number: 174649-09-3

Molecular Formula: C15H19FN2O6S

Molecular Weight: 374.3846

MDL Number: MFCD18070719

SMILES: O=C1O[C@H](CN1c1ccc(c(c1)F)N1CCOCC1)COS(=O)(=O)C

Properties

BP: 592.7±50.0°C at 760 mmHg

Form: Solid

MP: 183-185℃

Storage: Keep in dry area;2-8℃;

Complexity: 577

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 1

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 25

Hydrogen Bond Acceptor Count: 8

Hydrogen Bond Donor Count: 0

Isotope Atom Count: 0

Rotatable Bond Count: 5

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 0.8

Upstream Synthesis Route

124-63-0

168828-82-8

174649-09-3

[1]Patent:WO2009/63505,2009,A2,.Locationinpatent:Page/Pagecolumn14

[2]Patent:EP2163547,2010,A1,.Locationinpatent:Page/Pagecolumn8

[3]Patent:WO2011/77310,2011,A1,.Locationinpatent:Page/Pagecolumn12;13

[4]SyntheticCommunications,2010,vol.40,#6,p.789-798

[5]Patent:WO2010/84514,2010,A2,.Locationinpatent:Page/Pagecolumn15

[6]Patent:WO2011/114210,2011,A2,.Locationinpatent:Page/Pagecolumn23

[7]J.Med.Chem.,1996,vol.39,#3,p.673-679

[8]TetrahedronLetters,1999,vol.40,#26,p.4855-4856

[9]ChemicalandPharmaceuticalBulletin,2001,vol.49,#4,p.353-360

[10]TetrahedronLetters,2006,vol.47,#38,p.6799-6802

[11]EuropeanJournalofMedicinalChemistry,2009,vol.44,#8,p.3217-3227

[12]OrganicandBiomolecularChemistry,2008,vol.6,#24,p.4634-4642

[13]Patent:WO2012/114355,2012,A1,.Locationinpatent:Page/Pagecolumn11

[14]Patent:WO2013/72923,2013,A1,.Locationinpatent:Page/Pagecolumn16-17

[15]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[16]Patent:US2013/324719,2013,A1,.Locationinpatent:Paragraph0022;0056-0057

[17]Patent:WO2015/68121,2015,A1,.Locationinpatent:Page/Pagecolumn15

[18]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

369-34-6

174649-09-3

[1]ChemicalandPharmaceuticalBulletin,2001,vol.49,#4,p.353-360

[2]J.Med.Chem.,1996,vol.39,#3,p.673-679

[3]Patent:WO2011/77310,2011,A1,

[4]Patent:WO2011/114210,2011,A2,

[5]Patent:WO2011/114210,2011,A2,

[6]Patent:WO2012/114355,2012,A1,

[7]Patent:WO2013/72923,2013,A1,

[8]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[9]Patent:US2013/324719,2013,A1,

[10]Patent:WO2015/68121,2015,A1,

[11]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

2689-39-6

174649-09-3

[1]ChemicalandPharmaceuticalBulletin,2001,vol.49,#4,p.353-360

[2]J.Med.Chem.,1996,vol.39,#3,p.673-679

[3]Patent:WO2011/77310,2011,A1,

[4]Patent:WO2011/114210,2011,A2,

[5]Patent:WO2011/114210,2011,A2,

[6]Patent:WO2012/114355,2012,A1,

[7]Patent:WO2013/72923,2013,A1,

[8]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[9]Patent:US2013/324719,2013,A1,

[10]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

93246-53-8

174649-09-3

[1]TetrahedronLetters,2006,vol.47,#38,p.6799-6802

[2]ChemicalandPharmaceuticalBulletin,2001,vol.49,#4,p.353-360

[3]J.Med.Chem.,1996,vol.39,#3,p.673-679

[4]Patent:WO2011/77310,2011,A1,

[5]Patent:WO2011/114210,2011,A2,

[6]Patent:WO2011/114210,2011,A2,

[7]Patent:WO2012/114355,2012,A1,

[8]Patent:WO2013/72923,2013,A1,

[9]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[10]Patent:US2013/324719,2013,A1,

[11]Patent:WO2015/68121,2015,A1,

[12]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

168828-81-7

174649-09-3

[1]J.Med.Chem.,1996,vol.39,#3,p.673-679

[2]Patent:WO2011/77310,2011,A1,

[3]Patent:WO2011/114210,2011,A2,

[4]Patent:WO2013/72923,2013,A1,

[5]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[6]Patent:WO2015/68121,2015,A1,

[7]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

Downstream Synthesis Route

124-63-0

168828-82-8

174649-09-3

[1]Patent:WO2009/63505,2009,A2.Locationinpatent:Page/Pagecolumn14

[2]Patent:EP2163547,2010,A1.Locationinpatent:Page/Pagecolumn8

[3]Patent:WO2011/77310,2011,A1.Locationinpatent:Page/Pagecolumn12;13

[4]SyntheticCommunications,2010,vol.40,p.789-798

[5]Patent:WO2010/84514,2010,A2.Locationinpatent:Page/Pagecolumn15

[6]Patent:WO2011/114210,2011,A2.Locationinpatent:Page/Pagecolumn23

[7]JournalofMedicinalChemistry,1996,vol.39,p.673-679

[8]TetrahedronLetters,1999,vol.40,p.4855-4856

[9]ChemicalandPharmaceuticalBulletin,2001,vol.49,p.353-360

[10]TetrahedronLetters,2006,vol.47,p.6799-6802

[11]EuropeanJournalofMedicinalChemistry,2009,vol.44,p.3217-3227

[12]OrganicandBiomolecularChemistry,2008,vol.6,p.4634-4642

[13]Patent:WO2012/114355,2012,A1.Locationinpatent:Page/Pagecolumn11

[14]Patent:WO2013/72923,2013,A1.Locationinpatent:Page/Pagecolumn16-17

[15]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[16]Patent:US2013/324719,2013,A1.Locationinpatent:Paragraph0022;0056-0057

[17]Patent:WO2015/68121,2015,A1.Locationinpatent:Page/Pagecolumn15

[18]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

174649-09-3

168828-84-0

[1]Patent:WO2009/63505,2009,A2.Locationinpatent:Page/Pagecolumn14

[2]Patent:WO2011/77310,2011,A1.Locationinpatent:Page/Pagecolumn13

[3]OrganicPreparationsandProceduresInternational,2011,vol.43,p.348-353

[4]JournalofMedicinalChemistry,1996,vol.39,p.673-679

[5]TetrahedronLetters,1999,vol.40,p.4855-4856

[6]ChemicalandPharmaceuticalBulletin,2001,vol.49,p.353-360

[7]BioorganicandMedicinalChemistry,2003,vol.11,p.35-41

[8]TetrahedronLetters,2006,vol.47,p.6799-6802

[9]EuropeanJournalofMedicinalChemistry,2009,vol.44,p.3217-3227

[10]OrganicandBiomolecularChemistry,2008,vol.6,p.4634-4642

[11]EuropeanJournalofMedicinalChemistry,2013,vol.69,p.779-785

[12]Patent:WO2015/68121,2015,A1.Locationinpatent:Page/Pagecolumn7;15;16

288-32-4

174649-09-3

(S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-imidazol-1-ylmethyl-oxazolidin-2-one

[1]BioorganicandMedicinalChemistry,2003,vol.11,p.35-41

85006-25-3

174649-09-3

503026-31-1

[1]EuropeanJournalofMedicinalChemistry,2015,vol.106,p.120-131

[2]BioorganicandMedicinalChemistry,2003,vol.11,p.35-41

3-(3-fluoro-4-morpholin-4-yl-phenylamino)-propan-1-ol

174649-09-3

[1]TetrahedronLetters,2006,vol.47,p.6799-6802

Building Blocks More >

175-97-3

2-Oxa-7-azaspiro[4.4]nonane

AA00200T | MFCD14581261

175137-31-2

Cyclopropylmethyl 2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate

AA00207Y | MFCD00068151

175203-07-3

5-Chloro-2-(methylsulfinoimidoyl)-3-(trifluoromethyl)pyridine 2,4,6-trimethylbenzenesulfonate

AA0020G2 | MFCD00068013

175276-40-1

5,7-Bis(trifluoromethyl)-3-cyanopyrazolo[1,5-a]pyrimidine

AA0020O9 | MFCD00084901

1753-68-0

2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol

AA0020U0 | MFCD00185950

17587-08-5

2-(2H-Tetrazol-5-yl)-ethanol

AA002166 | MFCD03856019

180-50-7

2,8-Diazaspiro[5.5]undecane

AA0021HU | MFCD11043254

18031-40-8

1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, (4S)-

AA0021UB | MFCD00001543

1806388-74-8

2,3-Difluoro-5-nitrobenzamide

AA002248 | MFCD27923305

180976-09-4

2-(N-Boc-methylamino)acetonitrile

AA0022FC | MFCD06658361